Last reviewed · How we verify

Tafluprost ophthalmic solution 0.0015% — Competitive Intelligence Brief

Tafluprost ophthalmic solution 0.0015% (Tafluprost ophthalmic solution 0.0015%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analogue. Area: Ophthalmology.

phase 3 Prostaglandin analogue Prostaglandin F2α receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Tafluprost ophthalmic solution 0.0015% (Tafluprost ophthalmic solution 0.0015%) — Santen Pharmaceutical Co., Ltd.. Tafluprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tafluprost ophthalmic solution 0.0015% TARGET Tafluprost ophthalmic solution 0.0015% Santen Pharmaceutical Co., Ltd. phase 3 Prostaglandin analogue Prostaglandin F2α receptor
Preservative-Free Tafluprost or vehicle Preservative-Free Tafluprost or vehicle Merck Sharp & Dohme LLC phase 3 Prostaglandin analogue Prostaglandin F2α receptor
Travoprost/ Timolol/ Azopt/ Brimonidine Travoprost/ Timolol/ Azopt/ Brimonidine Singapore Eye Research Institute phase 3 Prostaglandin analogue, Beta blocker, Carbonic anhydrase inhibitor, Alpha-2 adrenergic agonist Prostaglandin F2α receptor, Beta-adrenergic receptor, Carbonic anhydrase, Alpha-2 adrenergic receptor
Misoprostol (given vaginally) Misoprostol (given vaginally) Hawler Medical University marketed Prostaglandin analogue Prostaglandin E1 receptor (EP receptor)
tafluprost and dorzolamide/timolol tafluprost and dorzolamide/timolol Aristotle University Of Thessaloniki marketed Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors
Misoprostol, per-oral tablets Misoprostol, per-oral tablets Tampere University Hospital marketed Prostaglandin analogue Prostaglandin E1 receptor (EP receptor)
Misoprostol, modified-release pessary Misoprostol, modified-release pessary Tampere University Hospital marketed Prostaglandin analogue Prostaglandin E1 receptor (EP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analogue class)

  1. Tampere University Hospital · 2 drugs in this class
  2. Allergan · 1 drug in this class
  3. Hawler Medical University · 1 drug in this class
  4. Ain Shams University · 1 drug in this class
  5. Merck Sharp & Dohme LLC · 1 drug in this class
  6. Santen Pharmaceutical Co., Ltd. · 1 drug in this class
  7. Mati Therapeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tafluprost ophthalmic solution 0.0015% — Competitive Intelligence Brief. https://druglandscape.com/ci/tafluprost-ophthalmic-solution-0-0015. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: